These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 22982784)

  • 1. Clinical outcomes of concomitant therapy of exenatide twice daily and basal insulin in patients with type 2 diabetes mellitus: a retrospective database analysis in the United States.
    Pawaskar M; Li Q; Hoogwerf BJ; Reynolds MW; Lee LJ; Fonseca V
    Endocr Pract; 2012; 18(5):700-11. PubMed ID: 22982784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting.
    Yoon NM; Cavaghan MK; Brunelle RL; Roach P
    Clin Ther; 2009 Jul; 31(7):1511-23. PubMed ID: 19695400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus.
    Levin PA; Mersey JH; Zhou S; Bromberger LA
    Endocr Pract; 2012; 18(1):17-25. PubMed ID: 21742605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic outcomes of matched patient populations initiating exenatide BID vs. insulin glargine in an ambulatory care setting.
    Pawaskar M; Li Q; Hoogwerf BJ; Reynolds MW; Faries D; Engelman W; Bruhn D; Bergenstal RM
    Diabetes Obes Metab; 2012 Jul; 14(7):626-33. PubMed ID: 22321776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
    Buse JB; Bergenstal RM; Glass LC; Heilmann CR; Lewis MS; Kwan AY; Hoogwerf BJ; Rosenstock J
    Ann Intern Med; 2011 Jan; 154(2):103-12. PubMed ID: 21138825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review.
    Best JH; Lavillotti K; DeYoung MB; Garrison LP
    Diabetes Obes Metab; 2012 May; 14(5):387-98. PubMed ID: 22074017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide.
    Pencek R; Brunell SC; Li Y; Hoogwerf BJ; Malone J
    Endocr Pract; 2012; 18(2):227-37. PubMed ID: 22446132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Glycemic Control from GLP-1RA Therapy with and Without Concurrent Insulin in Patients with Type 2 Diabetes.
    Singhal M; Unni S; Schauerhamer M; Nguyen H; Hurd J; McAdam-Marx C
    J Manag Care Spec Pharm; 2017 Mar; 23(3):267-275. PubMed ID: 28230449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic outcomes of elderly patient populations initiating exenatide BID versus insulin glargine in an ambulatory care setting.
    Pawaskar M; Li Q; Reynolds MW
    Curr Med Res Opin; 2012 Jun; 28(6):991-7. PubMed ID: 22519390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.
    Grimm M; Han J; Weaver C; Griffin P; Schulteis CT; Dong H; Malloy J
    Postgrad Med; 2013 May; 125(3):47-57. PubMed ID: 23748506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of exenatide twice daily compared to insulin lispro added to basal insulin in Latin American patients with type 2 diabetes: A retrospective analysis of the 4B trial.
    de Lapertosa SB; Frechtel G; Hardy E; Sauque-Reyna L
    Diabetes Res Clin Pract; 2016 Dec; 122():38-45. PubMed ID: 27776251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin.
    Viswanathan P; Chaudhuri A; Bhatia R; Al-Atrash F; Mohanty P; Dandona P
    Endocr Pract; 2007 Sep; 13(5):444-50. PubMed ID: 17872344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
    Moretto TJ; Milton DR; Ridge TD; Macconell LA; Okerson T; Wolka AM; Brodows RG
    Clin Ther; 2008 Aug; 30(8):1448-60. PubMed ID: 18803987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy.
    Traina AN; Lull ME; Hui AC; Zahorian TM; Lyons-Patterson J
    Can J Diabetes; 2014 Aug; 38(4):269-72. PubMed ID: 24797495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting.
    Brixner DI; McAdam-Marx C; Ye X; Boye KS; Nielsen LL; Wintle M; Misurski D; Fabunmi R
    Diabetes Obes Metab; 2009 Dec; 11(12):1122-30. PubMed ID: 19930004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Summaries for patients: Does adding exenatide to insulin treatment benefit patients with type 2 diabetes?
    Ann Intern Med; 2011 Jan; 154(2):I-40. PubMed ID: 21135289
    [No Abstract]   [Full Text] [Related]  

  • 17. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.
    Levin P; Wei W; Wang L; Pan C; Douglas D; Baser O
    Curr Med Res Opin; 2012 Mar; 28(3):439-46. PubMed ID: 22216894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes.
    Secnik Boye K; Matza LS; Oglesby A; Malley K; Kim S; Hayes RP; Brodows R
    Health Qual Life Outcomes; 2006 Oct; 4():80. PubMed ID: 17034640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
    Blevins T; Pullman J; Malloy J; Yan P; Taylor K; Schulteis C; Trautmann M; Porter L
    J Clin Endocrinol Metab; 2011 May; 96(5):1301-10. PubMed ID: 21307137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient factors associated with glucagonlike peptide 1 receptor agonist use with and without insulin.
    Hirsch IB; Xu Y; Davis KL; Calingaert B
    Endocr Pract; 2011; 17(5):707-16. PubMed ID: 21856602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.